AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00632931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo (unspecified)
Description: A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
Study NCT02226926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggrenox
Study NCT02226926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Persantin Retard
Study NCT02226926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Study NCT02348359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82
Study NCT02348359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Study NCT02348359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-VEGF
Study NCT02348359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01955109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250 mcg
Description: Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
Study NCT01122784 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rF1V vaccine (with Adjuvant)
Description: 80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
Study NCT01122784 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rF1V vaccine (without Adjuvant)
Description: 80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
Study NCT01122784 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rF1V vaccine (with Adjuvant)
Description: 80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
Study NCT01122784 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rF1V vaccine (without Adjuvant)
Description: 80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
Study NCT00586508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligrams (mg) loading dose then 500 or 875 mg, orally, daily, 4-week cycles with participants evaluated after each cycle. The dose difference is for participants who are on enzyme-inducing antiepileptic drugs (EIAED) versus non-enzyme inducing antiepileptic drugs (NEIAED).
Study NCT00586508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 milligrams per kilogram (mg/kg), intravenously (IV), every 2 weeks, participants are evaluated after each cycle (4-week cycles).
Study NCT00586508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzyme-inducing antiepileptic drugs (EIAED)
Description: Administered orally
Study NCT00586508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-enzyme inducing antiepileptic drugs (NEIAED)
Description: Administered orally
Study NCT00622596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Access
Description: Subjects would access buprenorphine through mobile access. On day 1: 8 mg of buprenorphine, then on Day 2: 16 mg daily of buprenorphine sublingually.
Study NCT02230540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SelfCath (comparator)
Description: Commercially available CE-marked catheter for urinary drainage.
Study NCT02230540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Product A SelfCath and urine bag, Conveen Security+
Description: SelfCath and urine bag, Conveen Security+ (both commercially available CE-marked devices).
Study NCT02230540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Product B SelfCath and urine bag, Conveen Contour
Description: SelfCath and urine bag, Conveen Contour (both commercially available CE-marked devices).
Study NCT02320682 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for Total Hip Arthroplasty (THA)
Description: THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.
Study NCT03745040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 20ml bupivacaine liposome injectable suspension 1.3% (266mg) + 50ml 0.25% Bupivacaine (150mg) + 70ml preservative-free 0.9% neutral saline
Study NCT02841956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Screen + Education (Phase 1)
Description: PHASE 1 Electronic Screening Arm + Targeted Education: Referral sources will receive the same standard targeted education as active comparator. In addition, the PQ-B (a 21 item screening questionnaire) will be administered to all patients at their first visit to the referral sites (e.g. intake) via an android tablet provided to the site for ease of administration and scoring. The investigators will provide multiple tablets per site so that the screening is available for more than one individual simultaneously and can be completed in any appropriate location. The investigators will allow paper-and-pencil administration for situations where it is more appropriate (e.g. emergency room).
Study NCT02841956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Provider Education (Phase 1)
Description: PHASE 1 Targeted Education Intervention: EDAPT standard targeted provider education1 focuses on increasing awareness about the signs of early psychosis \& building collaborative relationships with community members so community members see EDAPT as a rapid, effective source of help. It consists of a 2-hour workshop describing: 1) how to identify specific early symptoms \& changes associated with the onset of psychotic illness, 2) the benefits of early intervention on treatment outcomes in psychosis, 3) the structure, philosophy \& treatment model of the EDAPT Clinic, and 4) procedures for expeditious referral to our program. Case-based vignettes are reviewed to ensure understanding of the key symptoms.
Study NCT02841956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Mobile Engagement (Phase 2)
Description: PHASE 2 Community-based Mobile Engagement: Clinical assessment appointments will take place at the EDAPT clinic or within the community, wherever the individual would prefer. With patients deemed eligible for EDAPT services, the EDAPT clinician will obtain vitals and contact the EDAPT psychiatrist with a telemedicine-enabled laptop to complete the psychiatric evaluation remotely. The psychiatrist will prescribe medications and order labs, as indicated. The EDAPT clinician will follow up with the individual within 5 days to determine if the prescribed medication regimen has started.
Study NCT02841956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic based Engagement (Phase 2)
Description: PHASE 2 Clinic-based Engagement: The clinical assessment appointment will be completed within the EDAPT clinic. If deemed eligible for EDAPT services, the individual will be scheduled for a clinic-based appointment with the EDAPT psychiatrist within 5 days, who will prescribe medications and order labs as indicated. The EDAPT clinician will follow up with the individual within 5 days of the psychiatric evaluation (by phone or in the clinic) to determine if the prescribed medication regimen has started.
Study NCT03078127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline (Huff-Cough alone)
Description: Subjects will provide two huffs (forced expiratory maneuver with open glottis) followed by a cough every six minutes for a total of six Huff-Coughs.
Study NCT00833898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paced respiration as part of PEPRR
Description: The FDA approved RESPeRATE™ is the size of a portable compact disk (CD) player with a visual display, an elastic belt-type respiratory sensor, and a set of headphones. During a relaxation session, the device analyzes respiratory pattern of the subject and creates a melody of pleasant tones selected by the subject (one for inhalation and one for exhalation). The subjects can observe a cartoon figure on the screen of the device that indicates their inhalation and exhalation. The subject synchronizes their breathing to these tones as the exhalation tone is gradually increased in duration with a target of less than 10 breaths/minute. Subjects were encouraged to use RESPeRATE 3-5 times a week for 20 minutes.
Study NCT03078127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oscillatory Positive Expiatory Pressure Device
Description: Subjects will use an Areobika® branded OPEP device (10 breaths through highest tolerated resistance) prior to undergoing a Huff-Cough. Subjects will use the device six times every six minutes.
Study NCT00833898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEPRR
Description: PEPRR consist of 8 sessions, each lasting approximately 60min. The first 4 sessions are weekly, followed by biweekly mtgs for the remaining 4 sessions. Sessions begin the week that the patient receives the transfusion of donor cells. Session 1-4 are conducted at the hospital where the patients receive their transplant. Once discharged from the hospital, sessions will be conducted at the outpatient BMT clinic to coincide with patients' post-transplant visits. Sessions are devoted to a separate topic with the goal of assisting the caregiver in development \& application of various stress-mgmt techniques such as effective problem-solving, identifying \& challenging cognitive distortions, relaxation techniques, coping skills training, effective use of social support \& goal setting.
Study NCT03078127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Body Vibration Platform
Description: Subjects will be seated on a PowerPlate® whole-body vibration platform for 90 seconds prior to Huff-Cough. Six intervals on the platform will be completed six minutes apart.
Study NCT03078127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Chest Wall Oscillatory Vest
Description: Subjects will use TheVest® using a standardized Minnesota Protocol divided into six, four-minute segments, each followed by a Huff-Cough.
Study NCT01965145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Description: Sterile solution administered subcutaneously
Study NCT01965145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution administered subcutaneously
Study NCT04528953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval walking and Qigong exercise
Description: Interval walking: The subjects will be asked to complete daily 30 minutes of walking in two 15-minute bouts with the rest interval for at least 0.5 an hour and not more than 2 hours between each bout.~Qigong exercise: mind-body exercise using the six healing sound Qigong exercise will be used because it is easy to learn, requires minimal physical capability, and can be performed even in a sitting body position.
Study NCT04528953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interval walking and Qigong exercise
Description: Interval walking: The subjects will be asked to complete daily 30 minutes of walking in two 15-minute bouts with the rest interval for at least 0.5 an hour and not more than 2 hours between each bout.~Qigong exercise: mind-body exercise using the six healing sound Qigong exercise will be used because it is easy to learn, requires minimal physical capability, and can be performed even in a sitting body position.
Study NCT03550183 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Patients with PD in the therapy group were given UC-MSCs by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1 month, 3 months, 6 months and 12 months were evaluated respectively the curative effect.
Study NCT01649297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients receive placebo matching empagliflozin (low dose qd)
Study NCT01649297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo matching empagliflozin (low dose bid)
Study NCT01649297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients receive placebo matching Empagliflozin (high dose qd)
Study NCT01649297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo matching Empagliflozin (high dose qd)
Study NCT01649297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin (low dose qd)
Description: Patients receive Empagliflozin low dose once daily
Study NCT01649297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients receive placebo matching empagliflozin (low dose bid)
Study NCT01649297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients receive placebo matching Empagliflozin (high dose bid)
Study NCT01649297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo matching Empagliflozin (high dose bid)
Study NCT01649297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo matching empagliflozin (low dose qd)
Study NCT04279782 — intervention group
Intervention type: OTHER
Intervention: Comprehensive treatment
Description: Comprehensive treatment includes antiviral therapy, antibiotics therapy, symptomatic treatment, supportive therapy.
Study NCT04022356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feetme Connected Soles
Description: Walk for 10 meters (and 30meters):~* By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphone- collection of data by smartphone~* By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers).~If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely.
Study NCT04022356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Feetme Connected Soles
Description: Walk for 10 meters (and 30meters):~* By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphone- collection of data by smartphone~* By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers).~If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely.
Study NCT02453854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group motivational interviewing
Description: Monthly group meetings were held for two hour sessions each month and verifiable (treatment fidelity checked) motivational interviewing employed in helping clients make health behaviour changes.
Study NCT02453854 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group motivational interviewing
Description: Monthly group meetings were held for two hour sessions each month and verifiable (treatment fidelity checked) motivational interviewing employed in helping clients make health behaviour changes.
Study NCT01715402 — intervention group
Intervention type: PROCEDURE
Intervention: liver surgery
Description: this intervention type includes hepatectomies; wedge; segmentectomies etc...
Study NCT00553982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patellar component
Description: Resurfacing with onlay technique
Study NCT00553982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No patellar component
Description: Trimming of osteophytes when appropriate
Study NCT05160194 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Positive Parenting Intervention
Description: The highly interactive GROW Program consists of 5 core modules and 1 optional, supplemental session. Each session is expected to take 15-20 minutes to complete, and at the end of each module, parents record a 5 minute special play time video interacting with their child to demonstrate the skills they learned in the session. Each online module is followed by a meeting with a trained therapist who will discuss their special play time video and the skills they are learning. Parents make their way through the 5 core modules sequentially before accessing the supplemental session that may be relevant to them.
Study NCT02303990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02303990 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT04294433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-hexa, Twinrix-Junior
Description: Vaccines administrated according to product monographs' recommendations
Study NCT04294433 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix-hexa, Twinrix-Junior
Description: Vaccines administrated according to product monographs' recommendations
Study NCT02476370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation program
Description: relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week programm, one introductory session and daily home practice
Study NCT02476370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: surgery education
Description: intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery
Study NCT01807416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant insertion and abutment connection
Description: After implant insertion (standard platform or switching platform) the titanium abutment (standard or flat) will be connected
Study NCT03447600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting
Description: 25% daily energy requirements every other day until study completion at >/=5% weight loss which is an average of 12 weeks.
Study NCT03447600 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous dietary restriction
Description: 25% daily energy requirements every other day until study completion at >/=5% weight loss which is an average of 12 weeks.
Study NCT02951572 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NIV
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Starting dose of >=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
Study NCT01649297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin (high dose qd)
Description: Patients receive Empagliflozin high dose once daily
Study NCT01649297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin (high dose bid)
Description: Patients receive Empagliflozin high dose split twice daily
Study NCT01649297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin (low dose bid)
Description: Patients receive Empagliflozin low dose split twice daily
Study NCT01858064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS-MPH
Description: Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
Study NCT02298855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualised follow-up
Description: Patients allocated to gynaecological cancer nurse specialist at the end of primary treatment. Follow-up is negotiated to suit their individual situation. Type of contact is flexible, primarily by telephone although some women may opt for face-to-face appointments. Patients will be assessed using a holistic guide to identify signs of disease progression, symptoms warranting intervention, and psychological issues. The nurses delivering the intervention are expert in the management of ovarian cancer and will work to a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to assist patients to manage troublesome symptoms and live with psychological discomfort.
Study NCT01839383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different dialysate calcium concentration
Study NCT04420897 — intervention group
Intervention type: PROCEDURE
Intervention: Arterial blood gas samples
Description: Blood gases taken during the operation will be analyzed retrospectively. Whether these results have an effect on graft survival will be examined by reaching their records in the postoperative period.
Study NCT01202409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
Study NCT00858247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
Study NCT00951964 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Polyphenon E before Placebo
Description: patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
Study NCT00951964 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo before treatment
Description: patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
Study NCT01061853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOPICAL SIROLIMUS (RAPAMUNE*)
Description: APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE\*)1mg/ml bid during 3 months